Elizabeth Yeu, MD

Results of the BRIO-I study, the first of 2 phase 3 clinical trials of Brimochol PF, a topical, fixed-dose combination for the treatment of presbyopia, have recently been released.

Cochair Elizabeth Yeu, MD, highlights what this program will mean for ophthalmologists, optometrists, and their patients.

Over the years, IKA has become an invaluable resource for eye care professionals.